A Novel Inflammation-Marker-Based Prognostic Model for Advanced Pulmonary Lymphoepithelioma-Like Carcinoma
Xueyuan Chen,1,* Tingting Liu,1,* Silang Mo,1,* Yuwen Yang,1 Xiang Chen,1 Shaodong Hong,1 Ting Zhou,1 Gang Chen,1 Yaxiong Zhang,1 Yuxiang Ma,2 Yuanzheng Ma,1 Li Zhang,1 Yuanyuan Zhao1 1Medical Oncology Department, State Key Laboratory of Oncology in South China, Guangdong Pro...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2025-02-01
|
| Series: | Journal of Inflammation Research |
| Subjects: | |
| Online Access: | https://www.dovepress.com/a-novel-inflammation-marker-based-prognostic-model-for-advanced-pulmon-peer-reviewed-fulltext-article-JIR |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850025341569990656 |
|---|---|
| author | Chen X Liu T Mo S Yang Y Chen X Hong S Zhou T Chen G Zhang Y Ma Y Ma Y Zhang L Zhao Y |
| author_facet | Chen X Liu T Mo S Yang Y Chen X Hong S Zhou T Chen G Zhang Y Ma Y Ma Y Zhang L Zhao Y |
| author_sort | Chen X |
| collection | DOAJ |
| description | Xueyuan Chen,1,* Tingting Liu,1,* Silang Mo,1,* Yuwen Yang,1 Xiang Chen,1 Shaodong Hong,1 Ting Zhou,1 Gang Chen,1 Yaxiong Zhang,1 Yuxiang Ma,2 Yuanzheng Ma,1 Li Zhang,1 Yuanyuan Zhao1 1Medical Oncology Department, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People’s Republic of China; 2Department of Clinical Research, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, People’s Republic of China*These authors contributed equally to this workCorrespondence: Li Zhang; Yuanyuan Zhao, Sun Yat-sen University Cancer Center, 651 Dong Feng Road East, Guangzhou, 510060, People’s Republic of China, Email zhangli@sysucc.org.cn; zhaoyy@sysucc.org.cnPurpose: This study aimed to investigate the prognostic value of inflammation markers for advanced pulmonary lymphoepithelioma-like carcinoma (PLELC) and develop an effective prognostic model based on inflammation markers to predict the overall survival (OS) of this population.Methods: Cox regression analysis was performed on 18 clinical and inflammation features, and a nomogram was created to predict overall survival (OS). The nomogram was evaluated by the concordance index (C-index), the time-dependent area under the receiver operating (ROC) curves (AUCs), calibration curves, and Decision Curve Analysis (DCA).Results: This study included a training cohort (n = 177) and a validation cohort (n = 77). The following variables were found to be independent prognostic factors for OS and used in the nomogram: Hepatitis B virus surface antigen status, gender, neutrophil-to-lymphocyte ratio (NLR), and C-reactive protein-to-albumin ratio (CAR). The C-indexes of the nomogram in the training and validation cohort were 0.740 (95% CI: 0.706– 0.747) and 0.733 (95% CI: 0.678– 0.788), respectively. Furthermore, time-dependent AUCs and well-fitted calibration curves showed good discriminative ability in both cohorts. Additionally, among the subset of EBV DNA data (n = 111), both ROC curve and DCA curve analysis demonstrated that the nomogram plus EBV DNA provided superior predictive performance compared to EBV DNA or the nomogram alone. Patients who received chemoimmunotherapy as the first-line treatment had better OS (not reached vs 44.4 months, P = 0.015) than those with chemotherapy alone and those who received immunotherapy at any line had better OS than those who never received it (not reached vs 31.0 months, P < 0.001).Conclusion: This study established and validated a prognostic nomogram model for patients with advanced PLELC. Combining the nomogram with EBV DNA more effectively predicted the prognosis of patients than the nomogram alone. Immunotherapy was found to be a critical treatment option for PLELC.Keywords: pulmonary lymphoepithelioma-like carcinoma, overall survival, inflammation markers, nomogram |
| format | Article |
| id | doaj-art-19fafd802c0e4ac8a27993e1f00a00fc |
| institution | DOAJ |
| issn | 1178-7031 |
| language | English |
| publishDate | 2025-02-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | Journal of Inflammation Research |
| spelling | doaj-art-19fafd802c0e4ac8a27993e1f00a00fc2025-08-20T03:00:51ZengDove Medical PressJournal of Inflammation Research1178-70312025-02-01Volume 1824332445100379A Novel Inflammation-Marker-Based Prognostic Model for Advanced Pulmonary Lymphoepithelioma-Like CarcinomaChen XLiu TMo SYang YChen XHong SZhou TChen GZhang YMa YMa YZhang LZhao YXueyuan Chen,1,* Tingting Liu,1,* Silang Mo,1,* Yuwen Yang,1 Xiang Chen,1 Shaodong Hong,1 Ting Zhou,1 Gang Chen,1 Yaxiong Zhang,1 Yuxiang Ma,2 Yuanzheng Ma,1 Li Zhang,1 Yuanyuan Zhao1 1Medical Oncology Department, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-Sen University Cancer Center, Guangzhou, 510060, People’s Republic of China; 2Department of Clinical Research, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, 510060, People’s Republic of China*These authors contributed equally to this workCorrespondence: Li Zhang; Yuanyuan Zhao, Sun Yat-sen University Cancer Center, 651 Dong Feng Road East, Guangzhou, 510060, People’s Republic of China, Email zhangli@sysucc.org.cn; zhaoyy@sysucc.org.cnPurpose: This study aimed to investigate the prognostic value of inflammation markers for advanced pulmonary lymphoepithelioma-like carcinoma (PLELC) and develop an effective prognostic model based on inflammation markers to predict the overall survival (OS) of this population.Methods: Cox regression analysis was performed on 18 clinical and inflammation features, and a nomogram was created to predict overall survival (OS). The nomogram was evaluated by the concordance index (C-index), the time-dependent area under the receiver operating (ROC) curves (AUCs), calibration curves, and Decision Curve Analysis (DCA).Results: This study included a training cohort (n = 177) and a validation cohort (n = 77). The following variables were found to be independent prognostic factors for OS and used in the nomogram: Hepatitis B virus surface antigen status, gender, neutrophil-to-lymphocyte ratio (NLR), and C-reactive protein-to-albumin ratio (CAR). The C-indexes of the nomogram in the training and validation cohort were 0.740 (95% CI: 0.706– 0.747) and 0.733 (95% CI: 0.678– 0.788), respectively. Furthermore, time-dependent AUCs and well-fitted calibration curves showed good discriminative ability in both cohorts. Additionally, among the subset of EBV DNA data (n = 111), both ROC curve and DCA curve analysis demonstrated that the nomogram plus EBV DNA provided superior predictive performance compared to EBV DNA or the nomogram alone. Patients who received chemoimmunotherapy as the first-line treatment had better OS (not reached vs 44.4 months, P = 0.015) than those with chemotherapy alone and those who received immunotherapy at any line had better OS than those who never received it (not reached vs 31.0 months, P < 0.001).Conclusion: This study established and validated a prognostic nomogram model for patients with advanced PLELC. Combining the nomogram with EBV DNA more effectively predicted the prognosis of patients than the nomogram alone. Immunotherapy was found to be a critical treatment option for PLELC.Keywords: pulmonary lymphoepithelioma-like carcinoma, overall survival, inflammation markers, nomogramhttps://www.dovepress.com/a-novel-inflammation-marker-based-prognostic-model-for-advanced-pulmon-peer-reviewed-fulltext-article-JIRpulmonary lymphoepithelioma-like carcinomaoverall survivalinflammation markersnomogram |
| spellingShingle | Chen X Liu T Mo S Yang Y Chen X Hong S Zhou T Chen G Zhang Y Ma Y Ma Y Zhang L Zhao Y A Novel Inflammation-Marker-Based Prognostic Model for Advanced Pulmonary Lymphoepithelioma-Like Carcinoma Journal of Inflammation Research pulmonary lymphoepithelioma-like carcinoma overall survival inflammation markers nomogram |
| title | A Novel Inflammation-Marker-Based Prognostic Model for Advanced Pulmonary Lymphoepithelioma-Like Carcinoma |
| title_full | A Novel Inflammation-Marker-Based Prognostic Model for Advanced Pulmonary Lymphoepithelioma-Like Carcinoma |
| title_fullStr | A Novel Inflammation-Marker-Based Prognostic Model for Advanced Pulmonary Lymphoepithelioma-Like Carcinoma |
| title_full_unstemmed | A Novel Inflammation-Marker-Based Prognostic Model for Advanced Pulmonary Lymphoepithelioma-Like Carcinoma |
| title_short | A Novel Inflammation-Marker-Based Prognostic Model for Advanced Pulmonary Lymphoepithelioma-Like Carcinoma |
| title_sort | novel inflammation marker based prognostic model for advanced pulmonary lymphoepithelioma like carcinoma |
| topic | pulmonary lymphoepithelioma-like carcinoma overall survival inflammation markers nomogram |
| url | https://www.dovepress.com/a-novel-inflammation-marker-based-prognostic-model-for-advanced-pulmon-peer-reviewed-fulltext-article-JIR |
| work_keys_str_mv | AT chenx anovelinflammationmarkerbasedprognosticmodelforadvancedpulmonarylymphoepitheliomalikecarcinoma AT liut anovelinflammationmarkerbasedprognosticmodelforadvancedpulmonarylymphoepitheliomalikecarcinoma AT mos anovelinflammationmarkerbasedprognosticmodelforadvancedpulmonarylymphoepitheliomalikecarcinoma AT yangy anovelinflammationmarkerbasedprognosticmodelforadvancedpulmonarylymphoepitheliomalikecarcinoma AT chenx anovelinflammationmarkerbasedprognosticmodelforadvancedpulmonarylymphoepitheliomalikecarcinoma AT hongs anovelinflammationmarkerbasedprognosticmodelforadvancedpulmonarylymphoepitheliomalikecarcinoma AT zhout anovelinflammationmarkerbasedprognosticmodelforadvancedpulmonarylymphoepitheliomalikecarcinoma AT cheng anovelinflammationmarkerbasedprognosticmodelforadvancedpulmonarylymphoepitheliomalikecarcinoma AT zhangy anovelinflammationmarkerbasedprognosticmodelforadvancedpulmonarylymphoepitheliomalikecarcinoma AT may anovelinflammationmarkerbasedprognosticmodelforadvancedpulmonarylymphoepitheliomalikecarcinoma AT may anovelinflammationmarkerbasedprognosticmodelforadvancedpulmonarylymphoepitheliomalikecarcinoma AT zhangl anovelinflammationmarkerbasedprognosticmodelforadvancedpulmonarylymphoepitheliomalikecarcinoma AT zhaoy anovelinflammationmarkerbasedprognosticmodelforadvancedpulmonarylymphoepitheliomalikecarcinoma AT chenx novelinflammationmarkerbasedprognosticmodelforadvancedpulmonarylymphoepitheliomalikecarcinoma AT liut novelinflammationmarkerbasedprognosticmodelforadvancedpulmonarylymphoepitheliomalikecarcinoma AT mos novelinflammationmarkerbasedprognosticmodelforadvancedpulmonarylymphoepitheliomalikecarcinoma AT yangy novelinflammationmarkerbasedprognosticmodelforadvancedpulmonarylymphoepitheliomalikecarcinoma AT chenx novelinflammationmarkerbasedprognosticmodelforadvancedpulmonarylymphoepitheliomalikecarcinoma AT hongs novelinflammationmarkerbasedprognosticmodelforadvancedpulmonarylymphoepitheliomalikecarcinoma AT zhout novelinflammationmarkerbasedprognosticmodelforadvancedpulmonarylymphoepitheliomalikecarcinoma AT cheng novelinflammationmarkerbasedprognosticmodelforadvancedpulmonarylymphoepitheliomalikecarcinoma AT zhangy novelinflammationmarkerbasedprognosticmodelforadvancedpulmonarylymphoepitheliomalikecarcinoma AT may novelinflammationmarkerbasedprognosticmodelforadvancedpulmonarylymphoepitheliomalikecarcinoma AT may novelinflammationmarkerbasedprognosticmodelforadvancedpulmonarylymphoepitheliomalikecarcinoma AT zhangl novelinflammationmarkerbasedprognosticmodelforadvancedpulmonarylymphoepitheliomalikecarcinoma AT zhaoy novelinflammationmarkerbasedprognosticmodelforadvancedpulmonarylymphoepitheliomalikecarcinoma |